FDA authorizes second genome sequencing test for SARS-CoV-2
The Food and Drug Administration recently issued an emergency use authorization for a next generation sequencing test to detect SARS-CoV-2 in respiratory specimens from individuals suspected of COVID-19 by their health care provider.
Laboratories certified under the Clinical Laboratory Improvement Amendments to perform high complexity tests can perform the SARS-CoV-2 NGS Assay test. For more information, see the fact sheet for health care providers.
Related News Articles
Headline
A study published April 8 by the Public Library of Science’s Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of…
Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…
Headline
Respiratory illness activity remains high across the country, according to the latest data from the Centers for Disease Control and Prevention. Seasonal flu…
Headline
The Occupational Safety and Health Administration Jan. 13 announced that it terminated efforts to establish a final COVID-19 safety standard to protect workers…
Headline
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…